NCT06279130 - Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

January 29, 2029

Study Completion Date

January 29, 2034

Conditions

Resectable MMR-deficient Solid TumorsResectable MMR-proficient Solid Tumors

Interventions

DRUG

botensilimab

Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

DRUG

balstilimab

Anti programmed cell death protein-1 (anti-PD1)

Trial Locations (1)

RECRUITING

The Netherlands Cancer Institute, Amsterdam